Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUADvance trial of Allo-QuadCAR01-T in relapsed or refractory B-cell malignancies
2025-521735-36-00Phase 2Authorised
- Sponsor
- AvenCell Therapeutics
- Start
- Dec 2025
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of AVC-203 in mature B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AvenCell Therapeutics. Primary endpoints: Dose-limiting toxicity incidence, Safety and tolerability and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
AVC-203
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-521735-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521735-36-00.